Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Broad Coverage of Genetically Diverse Strains of Clostridium difficile by Actoxumab and Bezlotoxumab Predicted by <i>In Vitro</i> Neutralization and Epitope Modeling

2 Dec 2014

Abstract excerpt

Clostridium difficile infections (CDIs) are the leading cause of hospital-acquired infectious diarrhea and primarily involve two exotoxins, TcdA and TcdB. Actoxumab and bezlotoxumab are human monoclonal antibodies that neutralize the cytotoxic/cytopathic effects of TcdA and TcdB, respectively. In a phase II clinical study, the actoxumab-bezlotoxumab combination reduced the rate of CDI recurrence in patients who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clostridium difficile and Clostridium perfringens research
Share to Microscopic Colitis
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25451052
DOI: 10.1128/aac.04433-14

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Broad Coverage of Genetically Diverse Strains of Clostridium difficile by Actoxumab and Bezlotoxumab Predicted by <i>In Vitro</i> Neutralization and Epitope ModelingPMID 25451052Read ↗

Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivoSemantic proximity Read ↗

Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.Semantic proximity Read ↗

Phylogenomics of 8,839 <i>Clostridioides difficile</i> genomes reveals recombination-driven evolution and diversification of toxin A and BSemantic proximity Read ↗

Phylogenomics of 8,839 Clostridioides difficile genomes reveals recombination-driven evolution and diversification of toxin A and B.Semantic proximity Read ↗

Ribotype Classification of Clostridioides difficile Isolates Is Not Predictive of the Amino Acid Sequence Diversity of the Toxin Virulence Factors TcdA and TcdBSemantic proximity Read ↗

Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of C. difficile toxin BSemantic proximity Read ↗

Functional analyses of epidemic Clostridioides difficile toxin B variants reveal their divergence in utilizing receptors and inducing pathology.Semantic proximity Read ↗

Subtyping analysis reveals new variants and accelerated evolution of Clostridioides difficile toxin B.Semantic proximity Read ↗

An Update on Clostridioides difficile Binary ToxinSemantic proximity Read ↗

A Modified R-Type Bacteriocin Specifically Targeting Clostridium difficile Prevents Colonization of Mice without Affecting Gut Microbiota DiversitySemantic proximity Read ↗

An Optimized, Synthetic DNA Vaccine Encoding the Toxin A and Toxin B Receptor Binding Domains of Clostridium difficile Induces Protective Antibody Responses In VivoSemantic proximity Read ↗

Virulence and genomic diversity among clinical isolates of ST1 (BI/NAP1/027) <i>Clostridioides difficile</i>Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.